Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cudetaxestat - Blade Therapeutics

Next Previous
Drug Profile

Cudetaxestat - Blade Therapeutics

Alternative Names: BLD-0409; PAT 409

Latest Information Update: 08 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmAkea Therapeutics
  • Developer Blade Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Benzoic acids; Halogenated hydrocarbons; Hepatoprotectants; Indoles; Organic sulfur compounds; Pyrazoles; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action ENPP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Phase I Liver disorders; Systemic scleroderma
  • Discontinued Cholangitis; Inflammatory bowel diseases; Kidney disorders; Non-alcoholic steatohepatitis; Scleroderma

Most Recent Events

  • 08 Feb 2023 3756390: kdm updated, PD data/AE data updated, HEs added
  • 21 Nov 2022 Phase-I clinical trials in Liver disorders in USA (PO) (Blade Therapeutics pipeline; November 2022)
  • 21 Nov 2022 Phase-I clinical trials in Systemic scleroderma in USA (unspecified route) (Blade Therapeutics pipeline; November 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top